Literature DB >> 22532069

Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.

Ann Van der Jeugd1, Katja Hochgräfe2, Tariq Ahmed1, Jochen M Decker2, Astrid Sydow3, Anne Hofmann3, Dan Wu2,3, Lars Messing2, Detlef Balschun1, Rudi D'Hooge1, Eva-Maria Mandelkow2,3.   

Abstract

Neurofibrillary lesions of abnormal Tau are hallmarks of Alzheimer disease and frontotemporal dementias. Our regulatable (Tet-OFF) mouse models of tauopathy express variants of human full-length Tau in the forebrain (CaMKIIα promoter) either with mutation ΔK280 (pro-aggregant) or ΔK280/I277P/I308P (anti-aggregant). Co-expression of luciferase enables in vivo quantification of gene expression by bioluminescence imaging. Pro-aggregant mice develop synapse loss and Tau-pathology including missorting, phosphorylation and early pretangle formation, whereas anti-aggregant mice do not. We correlated hippocampal Tau pathology with learning/memory performance and synaptic plasticity. Pro-aggregant mice at 16 months of gene expression exhibited severe cognitive deficits in Morris water maze and in passive-avoidance paradigms, whereas anti-aggregant mice were comparable to controls. Cognitive impairment of pro-aggregant mice was accompanied by loss of hippocampal LTP in CA1 and CA3 areas and by a reduction of synaptic proteins and dendritic spines, although no neuronal loss was observed. Remarkably, memory and LTP recovered when pro-aggregant Tau was switched-OFF for ~4 months, Tau phosphorylation and missorting were reversed, and synapses recovered. Moreover, soluble and insoluble pro-aggregant hTau40 disappeared, while insoluble mouse Tau was still present. This study links early Tau pathology without neurofibrillary tangles and neuronal death to cognitive decline and synaptic dysfunction. It demonstrates that Tau-induced impairments are reversible after switching-OFF pro-aggregant Tau. Therefore, our mouse model may mimic an early phase of AD when the hippocampus does not yet suffer from irreversible cell death but cognitive deficits are already striking. It offers potential to evaluate drugs with regard to learning and memory performance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532069      PMCID: PMC4979687          DOI: 10.1007/s00401-012-0987-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  82 in total

Review 1.  Structure and function of dendritic spines.

Authors:  Esther A Nimchinsky; Bernardo L Sabatini; Karel Svoboda
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

2.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

3.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

Review 4.  Alzheimer's disease: old problem, new views from transgenic and viral models.

Authors:  Tomasz Jaworski; Ilse Dewachter; Claire Marie Seymour; Peter Borghgraef; Herman Devijver; Sebastian Kügler; Fred Van Leuven
Journal:  Biochim Biophys Acta       Date:  2010-03-21

5.  Induction of sharp wave-ripple complexes in vitro and reorganization of hippocampal networks.

Authors:  Christoph J Behrens; Leander P van den Boom; Livia de Hoz; Alon Friedman; Uwe Heinemann
Journal:  Nat Neurosci       Date:  2005-10-16       Impact factor: 24.884

6.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

7.  Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice.

Authors:  Anna Kremer; Hervé Maurin; David Demedts; Herman Devijver; Peter Borghgraef; Fred Van Leuven
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

8.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

9.  Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.

Authors:  Ana Ricobaraza; Mar Cuadrado-Tejedor; Sonia Marco; Isabel Pérez-Otaño; Ana García-Osta
Journal:  Hippocampus       Date:  2010-11-10       Impact factor: 3.899

10.  Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.

Authors:  Gary W Arendash; Jada Lewis; Ralph E Leighty; Eileen McGowan; Jennifer R Cracchiolo; Mike Hutton; Marcos F Garcia
Journal:  Brain Res       Date:  2004-06-25       Impact factor: 3.252

View more
  59 in total

Review 1.  The neuropathology of chronic traumatic encephalopathy.

Authors:  Ann C McKee; Thor D Stein; Patrick T Kiernan; Victor E Alvarez
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

2.  Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.

Authors:  Michiyo Iba; Jennifer D McBride; Jing L Guo; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2015-07-07       Impact factor: 17.088

Review 3.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

4.  Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture.

Authors:  Hans Zempel; Frank J A Dennissen; Yatender Kumar; Julia Luedtke; Jacek Biernat; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

Review 5.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

6.  Maturation and phenotype of pathophysiological neuronal excitability of human cells in tau-related dementia.

Authors:  Olga Kopach; Noemí Esteras; Selina Wray; Dmitri A Rusakov; Andrey Y Abramov
Journal:  J Cell Sci       Date:  2020-05-27       Impact factor: 5.285

Review 7.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

Review 8.  The Pathophysiology of Tau and Stress Granules in Disease.

Authors:  Anna Cruz; Mamta Verma; Benjamin Wolozin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 9.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

10.  Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280.

Authors:  Frank J A Dennissen; Marta Anglada-Huguet; Astrid Sydow; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.